A small team of graduate researchers has returned to the Love Lab with a mission: generate and test preclinical materials to help develop an affordable, accessible COVID-19 vaccine for large-scale production on a lightning-speed timeline. Although there are efforts underway across the globe to manufacture vaccines in the hundreds of millions, billions of doses may be necessary. To address this gap, the researchers are deploying a strategy developed under a Grand Challenge for ultra-low cost vaccines and are now simultaneously testing their first candidate component for a vaccine and optimizing the manufacturing process. The concurrent approach allows the team to develop vaccine components with manufacturability in mind from the start and potentially compresses the timeline from benchtop to full-scale production.